Company

Secretome Therapeutics

Secretome Therapeutics develops therapies from neonatal cardiac progenitor cells for cardiovascular diseases.

About

Secretome Therapeutics develops therapies from neonatal cardiac progenitor cells, including candidates targeting heart failure and dilated cardiomyopathy. Its products include STM-01 and STM-21. Founded in 2018, the company is based in Baltimore, US. It raised USD 30 million in Series A funding from RA Capital Management in May 2026 to advance STM-01 for Duchenne-associated cardiomyopathy.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in